Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2
Identifieur interne : 00D718 ( Main/Merge ); précédent : 00D717; suivant : 00D719Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2
Auteurs : P. Brooks [Australie] ; P. Emery [Royaume-Uni] ; J. F. Evans [États-Unis] ; H. Fenner [Suisse] ; C. J. Hawkey [Royaume-Uni] ; C. Patrono [Italie] ; J. Smolen [Autriche] ; F. Breedveld [Pays-Bas] ; R. Day [Australie] ; M. Dougados [France] ; E. W. Ehrich [États-Unis] ; J. Gijon-Banos [Espagne] ; T. K. Kvien [Norvège] ; M. H. Van Rijswijk [Pays-Bas] ; T. Warner [Royaume-Uni] ; H. Zeidler [Allemagne]Source :
- Rheumatology:(Oxford) [ 1462-0324 ] ; 1999.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Pharmacologie, Homme.
English descriptors
- KwdEn :
Abstract
The International Consensus Meeting on the Mode of Action of COX-2 Inhibition (ICMMAC) brought together 17 international experts in arthritis, gastroenterology and pharmacology on 5-6 December 1997. The meeting was convened to provide a definition of COX-2 specificity and to consider the clinical relevance of COX-2-specific agents. These compounds are a new class of drugs that specifically inhibit the enzyme COX-2 while having no effect on COX-1 across the whole therapeutic dose range. The objectives of the meeting were to review the currently available data regarding the roles and biology of COX-1 and COX-2, and to foster a consensus definition on COX-2 specificity. At the present time, no guidelines exist for the in vitro and in vivo assessment of COX specificity, and it was felt that consensus discussion might clarify some of these issues. The meeting also reviewed recent clinical data on COX-2-specific inhibitors. The following article reflects discussion at this meeting and provides a consensus definition of COX-2-specific inhibitors.
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 006229
- to stream PascalFrancis, to step Curation: 006E25
- to stream PascalFrancis, to step Checkpoint: 006005
Links to Exploration step
Pascal:99-0464747Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2</title><author><name sortKey="Brooks, P" sort="Brooks, P" uniqKey="Brooks P" first="P." last="Brooks">P. Brooks</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Faculty of Health Sciences, University of Queensland</s1><s3>AUS</s3><sZ>1 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Faculty of Health Sciences, University of Queensland</wicri:noRegion></affiliation></author><author><name sortKey="Emery, P" sort="Emery, P" uniqKey="Emery P" first="P." last="Emery">P. Emery</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Rheumatology and Rehabilitation Research Unit, Research School of Medicine, University of Leeds</s1><s3>GBR</s3><sZ>2 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Leeds</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Yorkshire-et-Humber</region></placeName><orgName type="university">Université de Leeds</orgName></affiliation></author><author><name sortKey="Evans, J F" sort="Evans, J F" uniqKey="Evans J" first="J. F." last="Evans">J. F. Evans</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Human Genetics Department, Merck & Co. Inc.</s1><s2>West Point, PA</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>West Point, PA</wicri:noRegion></affiliation></author><author><name sortKey="Fenner, H" sort="Fenner, H" uniqKey="Fenner H" first="H." last="Fenner">H. Fenner</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Swiss Federal Institute of Technology</s1><s2>Zurich</s2><s3>CHE</s3><sZ>4 aut.</sZ></inist:fA14><country>Suisse</country><wicri:noRegion>Swiss Federal Institute of Technology</wicri:noRegion></affiliation></author><author><name sortKey="Hawkey, C J" sort="Hawkey, C J" uniqKey="Hawkey C" first="C. J." last="Hawkey">C. J. Hawkey</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Division of Gastroenterology, University Hospital</s1><s2>Nottingham</s2><s3>GBR</s3><sZ>5 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Nottingham</wicri:noRegion></affiliation></author><author><name sortKey="Patrono, C" sort="Patrono, C" uniqKey="Patrono C" first="C." last="Patrono">C. Patrono</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Università di Chieti ' G.D'Annunzio', Cattedra di Farmacologia 1</s1><s2>Chieti</s2><s3>ITA</s3><sZ>6 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Chieti</wicri:noRegion></affiliation></author><author><name sortKey="Smolen, J" sort="Smolen, J" uniqKey="Smolen J" first="J." last="Smolen">J. Smolen</name><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>2nd Department of Medicine, Lainz Hospital</s1><s2>Vienna</s2><s3>AUT</s3><sZ>7 aut.</sZ></inist:fA14><country>Autriche</country><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Breedveld, F" sort="Breedveld, F" uniqKey="Breedveld F" first="F." last="Breedveld">F. Breedveld</name><affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Leiden University Hospital, Department of Rheumatology</s1><s2>Leiden</s2><s3>NLD</s3><sZ>8 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Leyde</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Day, R" sort="Day, R" uniqKey="Day R" first="R." last="Day">R. Day</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>St Vincent's Hospital</s1><s2>Darlinghurst, NSW</s2><s3>AUS</s3><sZ>9 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>St Vincent's Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Dougados, M" sort="Dougados, M" uniqKey="Dougados M" first="M." last="Dougados">M. Dougados</name><affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Institut de Rheumatologie, Hospital Cochin</s1><s2>Paris</s2><s3>FRA</s3><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Ehrich, E W" sort="Ehrich, E W" uniqKey="Ehrich E" first="E. W." last="Ehrich">E. W. Ehrich</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Merck & Co. Inc.</s1><s2>Rahway, NJ</s2><s3>USA</s3><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Merck & Co. Inc.</wicri:noRegion></affiliation></author><author><name sortKey="Gijon Banos, J" sort="Gijon Banos, J" uniqKey="Gijon Banos J" first="J." last="Gijon-Banos">J. Gijon-Banos</name><affiliation wicri:level="3"><inist:fA14 i1="12"><s1>University Hospital</s1><s2>Madrid</s2><s3>ESP</s3><sZ>12 aut.</sZ></inist:fA14><country>Espagne</country><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Kvien, T K" sort="Kvien, T K" uniqKey="Kvien T" first="T. K." last="Kvien">T. K. Kvien</name><affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Oslo City Department of Rheumatology, Diakonhjemmet Hospital</s1><s3>NOR</s3><sZ>13 aut.</sZ></inist:fA14><country>Norvège</country><wicri:noRegion>Oslo City Department of Rheumatology, Diakonhjemmet Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Van Rijswijk, M H" sort="Van Rijswijk, M H" uniqKey="Van Rijswijk M" first="M. H." last="Van Rijswijk">M. H. Van Rijswijk</name><affiliation wicri:level="3"><inist:fA14 i1="14"><s1>Department of Rheumatology, University Hospital</s1><s2>Groningen</s2><s3>NLD</s3><sZ>14 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation></author><author><name sortKey="Warner, T" sort="Warner, T" uniqKey="Warner T" first="T." last="Warner">T. Warner</name><affiliation wicri:level="3"><inist:fA14 i1="15"><s1>Vascular Inflammation, The William Harvey Research Institute, St Bartholomew's & The Royal London School of Medicine and Dentistry</s1><s2>London</s2><s3>GBR</s3><sZ>15 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Zeidler, H" sort="Zeidler, H" uniqKey="Zeidler H" first="H." last="Zeidler">H. Zeidler</name><affiliation wicri:level="1"><inist:fA14 i1="16"><s1>Department of Internal Medicine and Rheumatology, Medizinische Hochschule Hanover</s1><s3>DEU</s3><sZ>16 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Medizinische Hochschule Hanover</wicri:noRegion><wicri:noRegion>Department of Internal Medicine and Rheumatology, Medizinische Hochschule Hanover</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">99-0464747</idno><date when="1999">1999</date><idno type="stanalyst">PASCAL 99-0464747 INIST</idno><idno type="RBID">Pascal:99-0464747</idno><idno type="wicri:Area/PascalFrancis/Corpus">006229</idno><idno type="wicri:Area/PascalFrancis/Curation">006E25</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">006005</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">006005</idno><idno type="wicri:doubleKey">1462-0324:1999:Brooks P:interpreting:the:clinical</idno><idno type="wicri:Area/Main/Merge">00D718</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2</title><author><name sortKey="Brooks, P" sort="Brooks, P" uniqKey="Brooks P" first="P." last="Brooks">P. Brooks</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Faculty of Health Sciences, University of Queensland</s1><s3>AUS</s3><sZ>1 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Faculty of Health Sciences, University of Queensland</wicri:noRegion></affiliation></author><author><name sortKey="Emery, P" sort="Emery, P" uniqKey="Emery P" first="P." last="Emery">P. Emery</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Rheumatology and Rehabilitation Research Unit, Research School of Medicine, University of Leeds</s1><s3>GBR</s3><sZ>2 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Leeds</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Yorkshire-et-Humber</region></placeName><orgName type="university">Université de Leeds</orgName></affiliation></author><author><name sortKey="Evans, J F" sort="Evans, J F" uniqKey="Evans J" first="J. F." last="Evans">J. F. Evans</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Human Genetics Department, Merck & Co. Inc.</s1><s2>West Point, PA</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>West Point, PA</wicri:noRegion></affiliation></author><author><name sortKey="Fenner, H" sort="Fenner, H" uniqKey="Fenner H" first="H." last="Fenner">H. Fenner</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Swiss Federal Institute of Technology</s1><s2>Zurich</s2><s3>CHE</s3><sZ>4 aut.</sZ></inist:fA14><country>Suisse</country><wicri:noRegion>Swiss Federal Institute of Technology</wicri:noRegion></affiliation></author><author><name sortKey="Hawkey, C J" sort="Hawkey, C J" uniqKey="Hawkey C" first="C. J." last="Hawkey">C. J. Hawkey</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Division of Gastroenterology, University Hospital</s1><s2>Nottingham</s2><s3>GBR</s3><sZ>5 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Nottingham</wicri:noRegion></affiliation></author><author><name sortKey="Patrono, C" sort="Patrono, C" uniqKey="Patrono C" first="C." last="Patrono">C. Patrono</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Università di Chieti ' G.D'Annunzio', Cattedra di Farmacologia 1</s1><s2>Chieti</s2><s3>ITA</s3><sZ>6 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Chieti</wicri:noRegion></affiliation></author><author><name sortKey="Smolen, J" sort="Smolen, J" uniqKey="Smolen J" first="J." last="Smolen">J. Smolen</name><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>2nd Department of Medicine, Lainz Hospital</s1><s2>Vienna</s2><s3>AUT</s3><sZ>7 aut.</sZ></inist:fA14><country>Autriche</country><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Breedveld, F" sort="Breedveld, F" uniqKey="Breedveld F" first="F." last="Breedveld">F. Breedveld</name><affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Leiden University Hospital, Department of Rheumatology</s1><s2>Leiden</s2><s3>NLD</s3><sZ>8 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Leyde</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Day, R" sort="Day, R" uniqKey="Day R" first="R." last="Day">R. Day</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>St Vincent's Hospital</s1><s2>Darlinghurst, NSW</s2><s3>AUS</s3><sZ>9 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>St Vincent's Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Dougados, M" sort="Dougados, M" uniqKey="Dougados M" first="M." last="Dougados">M. Dougados</name><affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Institut de Rheumatologie, Hospital Cochin</s1><s2>Paris</s2><s3>FRA</s3><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Ehrich, E W" sort="Ehrich, E W" uniqKey="Ehrich E" first="E. W." last="Ehrich">E. W. Ehrich</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Merck & Co. Inc.</s1><s2>Rahway, NJ</s2><s3>USA</s3><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Merck & Co. Inc.</wicri:noRegion></affiliation></author><author><name sortKey="Gijon Banos, J" sort="Gijon Banos, J" uniqKey="Gijon Banos J" first="J." last="Gijon-Banos">J. Gijon-Banos</name><affiliation wicri:level="3"><inist:fA14 i1="12"><s1>University Hospital</s1><s2>Madrid</s2><s3>ESP</s3><sZ>12 aut.</sZ></inist:fA14><country>Espagne</country><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Kvien, T K" sort="Kvien, T K" uniqKey="Kvien T" first="T. K." last="Kvien">T. K. Kvien</name><affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Oslo City Department of Rheumatology, Diakonhjemmet Hospital</s1><s3>NOR</s3><sZ>13 aut.</sZ></inist:fA14><country>Norvège</country><wicri:noRegion>Oslo City Department of Rheumatology, Diakonhjemmet Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Van Rijswijk, M H" sort="Van Rijswijk, M H" uniqKey="Van Rijswijk M" first="M. H." last="Van Rijswijk">M. H. Van Rijswijk</name><affiliation wicri:level="3"><inist:fA14 i1="14"><s1>Department of Rheumatology, University Hospital</s1><s2>Groningen</s2><s3>NLD</s3><sZ>14 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation></author><author><name sortKey="Warner, T" sort="Warner, T" uniqKey="Warner T" first="T." last="Warner">T. Warner</name><affiliation wicri:level="3"><inist:fA14 i1="15"><s1>Vascular Inflammation, The William Harvey Research Institute, St Bartholomew's & The Royal London School of Medicine and Dentistry</s1><s2>London</s2><s3>GBR</s3><sZ>15 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Zeidler, H" sort="Zeidler, H" uniqKey="Zeidler H" first="H." last="Zeidler">H. Zeidler</name><affiliation wicri:level="1"><inist:fA14 i1="16"><s1>Department of Internal Medicine and Rheumatology, Medizinische Hochschule Hanover</s1><s3>DEU</s3><sZ>16 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Medizinische Hochschule Hanover</wicri:noRegion><wicri:noRegion>Department of Internal Medicine and Rheumatology, Medizinische Hochschule Hanover</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Rheumatology:(Oxford)</title><idno type="ISSN">1462-0324</idno><imprint><date when="1999">1999</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Rheumatology:(Oxford)</title><idno type="ISSN">1462-0324</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Chemotherapy</term><term>Human</term><term>In vitro</term><term>In vivo</term><term>Isozyme</term><term>Mechanism of action</term><term>Molecular form</term><term>Non steroidal antiinflammatory agent</term><term>Pharmacology</term><term>Prostaglandin-endoperoxide synthase</term><term>Specificity</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Antiinflammatoire non stéroïde</term><term>Prostaglandin-endoperoxide synthase</term><term>Isozyme</term><term>Forme moléculaire</term><term>Pharmacologie</term><term>Mécanisme action</term><term>Spécificité</term><term>In vitro</term><term>In vivo</term><term>Homme</term><term>Traitement</term><term>Chimiothérapie</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Pharmacologie</term><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The International Consensus Meeting on the Mode of Action of COX-2 Inhibition (ICMMAC) brought together 17 international experts in arthritis, gastroenterology and pharmacology on 5-6 December 1997. The meeting was convened to provide a definition of COX-2 specificity and to consider the clinical relevance of COX-2-specific agents. These compounds are a new class of drugs that specifically inhibit the enzyme COX-2 while having no effect on COX-1 across the whole therapeutic dose range. The objectives of the meeting were to review the currently available data regarding the roles and biology of COX-1 and COX-2, and to foster a consensus definition on COX-2 specificity. At the present time, no guidelines exist for the in vitro and in vivo assessment of COX specificity, and it was felt that consensus discussion might clarify some of these issues. The meeting also reviewed recent clinical data on COX-2-specific inhibitors. The following article reflects discussion at this meeting and provides a consensus definition of COX-2-specific inhibitors.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Autriche</li><li>Espagne</li><li>France</li><li>Italie</li><li>Norvège</li><li>Pays-Bas</li><li>Royaume-Uni</li><li>Suisse</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Communauté de Madrid</li><li>Grand Londres</li><li>Groningue (province)</li><li>Hollande-Méridionale</li><li>Vienne (Autriche)</li><li>Yorkshire-et-Humber</li><li>Île-de-France</li></region><settlement><li>Groningue</li><li>Leeds</li><li>Leyde</li><li>Londres</li><li>Madrid</li><li>Paris</li><li>Vienne (Autriche)</li></settlement><orgName><li>Université de Leeds</li></orgName></list><tree><country name="Australie"><noRegion><name sortKey="Brooks, P" sort="Brooks, P" uniqKey="Brooks P" first="P." last="Brooks">P. Brooks</name></noRegion><name sortKey="Day, R" sort="Day, R" uniqKey="Day R" first="R." last="Day">R. Day</name></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Emery, P" sort="Emery, P" uniqKey="Emery P" first="P." last="Emery">P. Emery</name></region><name sortKey="Hawkey, C J" sort="Hawkey, C J" uniqKey="Hawkey C" first="C. J." last="Hawkey">C. J. Hawkey</name><name sortKey="Warner, T" sort="Warner, T" uniqKey="Warner T" first="T." last="Warner">T. Warner</name></country><country name="États-Unis"><noRegion><name sortKey="Evans, J F" sort="Evans, J F" uniqKey="Evans J" first="J. F." last="Evans">J. F. Evans</name></noRegion><name sortKey="Ehrich, E W" sort="Ehrich, E W" uniqKey="Ehrich E" first="E. W." last="Ehrich">E. W. Ehrich</name></country><country name="Suisse"><noRegion><name sortKey="Fenner, H" sort="Fenner, H" uniqKey="Fenner H" first="H." last="Fenner">H. Fenner</name></noRegion></country><country name="Italie"><noRegion><name sortKey="Patrono, C" sort="Patrono, C" uniqKey="Patrono C" first="C." last="Patrono">C. Patrono</name></noRegion></country><country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Smolen, J" sort="Smolen, J" uniqKey="Smolen J" first="J." last="Smolen">J. Smolen</name></region></country><country name="Pays-Bas"><region name="Hollande-Méridionale"><name sortKey="Breedveld, F" sort="Breedveld, F" uniqKey="Breedveld F" first="F." last="Breedveld">F. Breedveld</name></region><name sortKey="Van Rijswijk, M H" sort="Van Rijswijk, M H" uniqKey="Van Rijswijk M" first="M. H." last="Van Rijswijk">M. H. Van Rijswijk</name></country><country name="France"><region name="Île-de-France"><name sortKey="Dougados, M" sort="Dougados, M" uniqKey="Dougados M" first="M." last="Dougados">M. Dougados</name></region></country><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Gijon Banos, J" sort="Gijon Banos, J" uniqKey="Gijon Banos J" first="J." last="Gijon-Banos">J. Gijon-Banos</name></region></country><country name="Norvège"><noRegion><name sortKey="Kvien, T K" sort="Kvien, T K" uniqKey="Kvien T" first="T. K." last="Kvien">T. K. Kvien</name></noRegion></country><country name="Allemagne"><noRegion><name sortKey="Zeidler, H" sort="Zeidler, H" uniqKey="Zeidler H" first="H." last="Zeidler">H. Zeidler</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00D718 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 00D718 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Merge
|type= RBID
|clé= Pascal:99-0464747
|texte= Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2
}}
| This area was generated with Dilib version V0.6.33. |  |